Tvardi Therapeutics Files for Up to $9.7M ATM Offering, Replacing Prior $12.5M Program After $11M in Sales
TVRD has more than doubled off its 52-week low of $1.5.
Summary
Tvardi Therapeutics filed a new ATM prospectus supplement for up to $9.7 million, replacing its prior $12.5 million ATM after selling $11 million in shares. The offering could dilute existing shareholders by roughly 25% and highlights the company's ongoing cash needs amid a going concern warning.
Key Events · Financing and Capital Events · TVRD
-
New ATM Prospectus for $9.7M
Tvardi filed a prospectus supplement for an at-the-market offering of up to $9,689,765, replacing the prior $12.5 million ATM prospectus after selling $11.0 million in shares.
-
Prior ATM Sales of $11M
Under the previous ATM, the company sold 3,110,769 shares for approximately $11.0 million in gross proceeds, leaving only $1.5 million remaining on that program.
-
Potential Dilution of ~25%
If fully utilized at the assumed $3.08 per share, the new ATM would add roughly 3.1 million shares, increasing the pro forma share count from 12.5 million to about 15.6 million — a 25% increase.
-
Going Concern and Cash Runway
The company has a going concern warning and its cash runway extends only into Q4 2026, making this ATM a critical source of near-term funding.
Analysis · TVRD · Life Sciences
Tvardi Therapeutics is reloading its at-the-market (ATM) equity program with a new prospectus supplement for up to $9.7 million, after having sold $11 million under the prior $12.5 million ATM. The company, which has a going concern warning and a market cap of only $30 million, is continuing to tap the market for survival capital. The new ATM represents significant potential dilution — if fully utilized at the assumed $3.08 price, it would add roughly 3.1 million shares, or about 25% of the current pro forma outstanding. This comes just 10 days after positive Phase 1 data for TTI-109, which may have been intended to support the stock price ahead of this filing. The offering is dilutive and underscores the company's urgent need for cash to fund operations and clinical trials.
At the time of this filing, TVRD was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30M. The 52-week trading range was $1.50 to $43.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.